MP1032

DRUG3 trials

Sponsors

MetrioPharm AG

Conditions

COVID-19Plaque PsoriasisPsoriasis

Phase 2

Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

CompletedNCT02908347

MetrioPharm AGPlaque Psoriasis, Psoriasis

Start: 2016-05-31End: 2017-02-28Updated: 2019-01-23

Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis

CompletedNCT03706209

MetrioPharm AGPsoriasis

Start: 2018-02-27End: 2019-06-12Updated: 2024-11-22

MP1032 Treatment in Patients With Moderate to Severe COVID-19

CompletedNCT04932941

MetrioPharm AGCOVID-19

Start: 2021-10-19End: 2022-09-05Updated: 2023-06-29